📊 RAPP Key Takeaways
Is Rapport Therapeutics, Inc. (RAPP) a Good Investment?
Rapport is a pre-revenue biotech company with no sales and burning $87.5M annually in operating cash, leaving only 7 months of cash runway at current burn rates. While the balance sheet is strong with $484.7M equity and zero debt, the company faces critical dependency on successful clinical trials, regulatory approval, and imminent capital raises to survive. Absent major near-term milestones or funding announcements, the cash depletion risk is severe and fundamentally unsustainable.
Why Buy Rapport Therapeutics, Inc. Stock? RAPP Key Strengths
- Fortress balance sheet with $484.7M stockholders equity and zero long-term debt
- Exceptional liquidity (26.17x current ratio) providing near-term operational flexibility
- Improving EPS trend year-over-year (+24.3%), indicating loss reduction relative to share base
RAPP Stock Risks: Rapport Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no commercial traction or sales generation capability
- Severe cash burn of -$87.5M annually with only ~6-7 months of runway at current rates
- Existential dependency on successful clinical trials, FDA approval, and external capital raises for survival
- Negative returns destroying shareholder value (ROE -23%, ROA -21.8%)
- High execution risk on pipeline drug candidates with no near-term revenue visibility
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Clinical trial progression, FDA milestone dates, and regulatory feedback
- Equity financing announcements, capital raise amounts, and burn rate sustainability
- Operating loss trajectory and path to first revenue-generating drug approval
Rapport Therapeutics, Inc. (RAPP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 26.17x current ratio provides a solid financial cushion.
RAPP Profit Margin, ROE & Profitability Analysis
RAPP vs Healthcare Sector: How Rapport Therapeutics, Inc. Compares
How Rapport Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rapport Therapeutics, Inc. Stock Overvalued? RAPP Valuation Analysis 2026
Based on fundamental analysis, Rapport Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rapport Therapeutics, Inc. Balance Sheet: RAPP Debt, Cash & Liquidity
RAPP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rapport Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.78 indicates the company is currently unprofitable.
RAPP Revenue Growth, EPS Growth & YoY Performance
Rapport Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
RAPP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rapport Therapeutics, Inc. (CIK: 0002012593)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RAPP
What is the AI rating for RAPP?
Rapport Therapeutics, Inc. (RAPP) has an AI rating of STRONG SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RAPP's key strengths?
Claude: Fortress balance sheet with $484.7M stockholders equity and zero long-term debt. Exceptional liquidity (26.17x current ratio) providing near-term operational flexibility.
What are the risks of investing in RAPP?
Claude: Pre-revenue stage with no commercial traction or sales generation capability. Severe cash burn of -$87.5M annually with only ~6-7 months of runway at current rates.
What is RAPP's revenue and growth?
Rapport Therapeutics, Inc. reported revenue of N/A.
Does RAPP pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
Where can I find RAPP SEC filings?
Official SEC filings for Rapport Therapeutics, Inc. (CIK: 0002012593) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RAPP's EPS?
Rapport Therapeutics, Inc. has a diluted EPS of $-2.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RAPP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rapport Therapeutics, Inc. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RAPP stock overvalued or undervalued?
Valuation metrics for RAPP: ROE of -23.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RAPP stock in 2026?
Our dual AI analysis gives Rapport Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RAPP's free cash flow?
Rapport Therapeutics, Inc.'s operating cash flow is $-87.5M, with capital expenditures of $616.0K.
How does RAPP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -23.0% (avg: 15%), current ratio 26.17 (avg: 2).